Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2020-10-29 Board/Management Inform…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
DIRECTORATE CHANGE
Board/Management Information Classification · 100% confidence The document is a Form 6-K filing with the SEC, which is used by foreign issuers to report material information. The content is an announcement of a change in the company's board of directors, specifically the appointment of a new Non-Executive Director. There are no financial statements or detailed management discussion, only a directorate change announcement. The document length is 4477 characters, which is relatively short and consistent with a directorate change notice. Therefore, the appropriate classification is Board/Management Information (MANG).
2020-10-29 English
Directorate Change
Board/Management Information Classification · 98% confidence The document is an official announcement disseminated via RNS (Regulatory News Service), indicated by the 'RNS Number' and the closing footer mentioning RNS and the London Stock Exchange. The core content announces the appointment of a new Non-Executive Director, Diana Layfield, effective November 1, 2020. This type of announcement—a change in the company's board of directors or senior management—directly corresponds to the definition for Board/Management Information (MANG). Although it is distributed via RNS, the specific content is highly targeted, making MANG the most accurate classification over the general RNS fallback.
2020-10-29 English
ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the FDA Priority Review granted to Enhertu for the treatment of HER2-positive metastatic gastric cancer, including clinical trial data, regulatory status, and collaboration details. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. This document is not an annual report, earnings release, or any other specific financial report but rather a regulatory announcement and update on drug development and approval status. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2020-10-28 English
FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the approval of Forxiga's cardiovascular outcomes benefit in China, including clinical trial data and regulatory approvals. The document does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It is an informational update about a regulatory and product approval event. Form 6-K filings are generally considered Regulatory Filings (RNS) as they provide miscellaneous updates from foreign issuers that do not fit into other specific categories like Annual Reports or Earnings Releases. The document length (8815 characters) and content confirm it is not merely an announcement of a report but a regulatory update report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-10-28 English
Enhertu US Priority Review in gastric cancer
Regulatory Filings Classification · 98% confidence The document is an official announcement released via RNS (RNS Number : 4502D) on October 28, 2020, by AstraZeneca PLC. The content details the acceptance of a supplemental Biologics License Application (sBLA) and the granting of Priority Review by the US FDA for the drug Enhertu for a specific cancer indication. This is a regulatory/clinical development update concerning a drug application status, not a full financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Since it is a specific regulatory announcement about a drug application milestone, it fits best under the general 'Regulatory Filings' category (RNS) as it is not covered by the more specific clinical/financial/corporate action codes. It is not a Report Publication Announcement (RPA) because it is reporting a specific regulatory action (Priority Review grant), not just announcing the publication of a separate report.
2020-10-28 English
Forxiga CV outcomes benefit approved in China
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and contains a date stamp (28 October 2020) typical of regulatory news service announcements. The content describes an update to a drug approval ('Forxiga cardiovascular outcomes benefit approved in China') based on clinical trial data. This is a specific corporate announcement regarding regulatory/market progress, not a comprehensive financial report (like 10-K or IR) or a transcript. Since it is a formal announcement distributed via RNS (London Stock Exchange's news service), and it doesn't fit perfectly into categories like DIV, ER, or CAP, the most appropriate classification is the general regulatory announcement category, RNS.
2020-10-28 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.